^
Association details:
| Biomarker: | KRAS wild-type |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) + Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Palbociclib and Cetuximab in Metastatic Colorectal Cancer
Excerpt:
...4.1.6 Documented wild-type in KRAS and NRAS (codons 12, 13, 59, 61, 117, and 146) and in BRAF codon 600, based on tumor tissue taken from primary or metastatic site and tested for biomarkers 4.1.7 Previously treated with at least two prior regimens of systemic chemotherapy for metastatic or locally advanced, unresectable disease, including fluoropyrimidines (5-fluorouracil and/or capecitabine), oxaliplatin, and irinotecan....
Trial ID:
Source:
Title:
Phase II Single-Arm Study of Palbociclib and Cetuximab Rechallenge in Patients with KRAS/NRAS/BRAF Wild-Type Colorectal Cancer
Published date:
10/26/2022
Excerpt:
...phase II trial of cetuximab and palbociclib in KRAS-WT mCRC...Median progression-free survival was 1.8 months and median overall survival was 6.6 months.
DOI:
10.1093/oncolo/oyac222
Trial ID:
Source:
Title:
Phase II single-arm study of palbociclib and cetuximab rechallenge in KRAS/NRAS/BRAF wild-type (KRAS WT) metastatic colorectal cancer (mCRC) patients (pts).
Published date:
01/18/2022
Excerpt:
LCCC1717 was a multicenter, single-arm, Simon’s two stage phase II study of cetuximab and palbociclib in KRAS WT mCRC treated with ≥2 prior regimens (NCT03446157)….3 pts (30%) had stable disease (SD), including 1 patient with SD for 24.7 months....Median PFS was 1.8 mo (95% CI: 1.7, NE) and median OS was 6.6 mo (95% CI: 3.6, NE).
Trial ID:
